HIV/AIDS Topics IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year
- Details
- Category: HIV Vaccines
- Published on Wednesday, 09 August 2017 00:00
- Written by Gus Cairns
A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the eighth human vaccine efficacy trial ever run in the history of the HIV epidemic, and the first since 2009.
IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
- Written by Gus Cairns
A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.
IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland
- Details
- Category: HIV Treatment
- Published on Friday, 28 July 2017 00:00
- Written by Keith Alcorn
New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.
IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
- Written by Liz Highleyman
A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.
IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
- Written by Gus Cairns
A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.
Web Design and Development by